intravenously with different vaccine formulations, such as multi-LP/α-GalCer
+ TRP2-mRNA, multi-LP/TRP2-mRNA, multi-LP/TRP2-mRNA + free α-GalCer,
free α-GalCer + TRP2-mRNA, and PBS as a negative control. The
vaccine formulations were prepared using 10 μg of TRP2-mRNA
and 0.5 μg of α-GalCer. Blood was collected from vaccinated
mice by saphenous bleeding and erythrocytes were removed by addition
of ACK lysis buffer (Quality Biological). peripheral blood mononuclear
cells (PBMCs) were stimulated with 1 μg/mL of TRP2-peptide (SVYDFFVWL)
for 6 h in the presence of a protein transport inhibitor, Brefeldin
A (BD GolgiPlug). After incubation, cells were washed and stained
with Abs for surface markers-TCRβ, CD8, and V450/viability dye.
Cells were then washed, fixed, and permeabilized with a BD Fixation/Permeabilization
Solution Kit and stained with anti-IFN-γ. The cells were washed,
resuspended in FACS buffer (1× PBS and 0.5% BSA), and analyzed
by flow cytometry (BD Fortessa X-20).
SVYDFFVWL-specific tetramer
(MBL International) staining was carried out by incubation at room
temperature for 10 min in FACS buffer. After washing, PBMCs were stained
with anti-TCRβ, anti-CD8 clone KT15, and V450/viability for
30 min at 4 °C in FACS buffer. Then, the samples were analyzed
by flow cytometry (BD Fortessa X-20).